-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

Benzinga·09/25/2026 12:32:08
Diffusion vocale
Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.